ClinicalTrials.gov Search Results 01/28/2021

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
1	NCT02887495	The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma) Study Documents:	Title Acronym: Other Ids: 051427	Recruiting	•Scleroderma		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Modified Rodnan Skin Score •Medsger Severity Score	Enrollment: 600 Age: 18 Years to 100 Years (Adult, Older Adult) Sex: All	•George Washington University	•Other	Study Start: July 2014 Primary Completion: July 2034 Study Completion: July 2040 First Posted: September 2, 2016 Results First Posted: No Results Posted Last Update Posted: January 7, 2019	•Victoria K Shanmugam, Washington, District of Columbia, United States
2	NCT01656447	Scleroderma Registry & Repository at the Hospital for Special Surgery Study Documents:	Title Acronym: Other Ids: 2014-276	Recruiting	•Scleroderma		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Modified Rodnan Skin Score •Scleroderma Health Assessment Questionnaire •Short Form-36	Enrollment: 300 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hospital for Special Surgery, New York	•Other	Study Start: August 2006 Primary Completion: January 2030 Study Completion: August 2012 First Posted: August 3, 2012 Results First Posted: No Results Posted Last Update Posted: September 17, 2020	•Hospital for Special Surgery, New York, New York, United States
3	NCT04319120	Pilot Study of Description of Cicatrisation Rates of Digital Ulcers in Systemic Scleroderma Study Documents:	Title Acronym: POPSUD Other Ids: 87RI18_0017	Recruiting	•Scleroderma, Systemic	•Other: questionnaires online	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Number of digital ulcers	Enrollment: 78 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Limoges	•Other	Study Start: December 17, 2020 Primary Completion: May 2022 Study Completion: October 2022 First Posted: March 24, 2020 Results First Posted: No Results Posted Last Update Posted: January 7, 2021	•Bordeaux Hospital, Bordeaux, France •Limoges Hospital, Limoges, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
4	NCT04491396	Yoga Adjunct for Scleroderma Study Documents:	Title Acronym: GYYB Other Ids: 12771	Recruiting	•Scleroderma	•Behavioral: Gentle Yoga and Yogic Breathing	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Quality of life determination: SHAQ-DI •Perceived Stress •Depression •Salivary biomarkers •Feasibility test •Adherence •Acceptance	Enrollment: 30 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Medical University of South Carolina •Richard Silver •Marvella Ford •Paul Nietert •Therese Killeen	•Other	Study Start: January 8, 2020 Primary Completion: July 2021 Study Completion: August 2021 First Posted: July 29, 2020 Results First Posted: No Results Posted Last Update Posted: January 22, 2021	•Medical University of South Carolina, Charleston, South Carolina, United States
5	NCT03262922	Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment Study Documents:	Title Acronym: PRESSY Other Ids: 35RC16_3032_PRE	Recruiting	•Systemic Scleroderma		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Other Outcome Measures: Questionnaire to evaluate the exposition of environmental and professional toxics	Enrollment: 250 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Rennes University Hospital	•Other	Study Start: July 29, 2016 Primary Completion: December 31, 2020 Study Completion: July 2021 First Posted: August 25, 2017 Results First Posted: No Results Posted Last Update Posted: January 7, 2020	•CHU de Rennes, Rennes, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
6	NCT03965780	The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED) Study Documents:	Title Acronym: SPIN-SSLED Other Ids: 17-112A	Recruiting	•Scleroderma, Systemic	•Other: SPIN-SSLED Program	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures: •Leader Self-Efficacy: Scleroderma Support Group Leader Self-efficacy Scale (SSGLSS) •Burnout •Leader Satisfaction with Leading a Support Group •Emotional Distress •Participant Satisfaction: SPIN-SSLED Program	Enrollment: 180 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Lady Davis Institute	•Other	Study Start: September 23, 2019 Primary Completion: February 2021 Study Completion: May 2021 First Posted: May 29, 2019 Results First Posted: No Results Posted Last Update Posted: November 12, 2019	•Jewish General Hospital, Montreal, Quebec, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
7	NCT04523506	The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma Study Documents:	Title Acronym: Other Ids: STU-2020-0169	Recruiting	•Scleroderma	•Biological: Botulinum toxin(Botox)	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Changes in inter-labial distance •Changes interincisal distance •quality of life via a Skindex16 survey •Changes in the inter-commissural distance •Changes in the Mouth Handicap in Systemic Sclerosis Scale (MHISS)	Enrollment: 30 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•University of Texas Southwestern Medical Center	•Other	Study Start: May 8, 2020 Primary Completion: May 2021 Study Completion: December 2021 First Posted: August 21, 2020 Results First Posted: No Results Posted Last Update Posted: August 21, 2020	•UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials, Dallas, Texas, United States
8	NCT04535245	Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD Study Documents:	Title Acronym: Other Ids: HS 3471	Recruiting	•Scleroderma	•Diagnostic Test: LCI testing	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: The Utility of Lung Clearance Index Scores at predicting Interstitial Lung disease (ILD) development within 5 years among Scleroderma patients without ILD.	Enrollment: 50 Age: 21 Years to 75 Years (Adult, Older Adult) Sex: All	•National Jewish Health	•Other	Study Start: January 4, 2021 Primary Completion: January 15, 2026 Study Completion: January 15, 2026 First Posted: September 1, 2020 Results First Posted: No Results Posted Last Update Posted: January 6, 2021	•National Jewish Health, Denver, Colorado, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
9	NCT04148716	microRNAs in Systemic Scleroderma Study Documents:	Title Acronym: Dig-ScS Other Ids: 19-AOI-07	Not yet recruiting	•Scleroderma, Systemic	•Procedure: additional biopsies	Study Type: Observational Phase: Study Design: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: description of the profile of miR based expression on cytokinic treatments and stimuli.	Enrollment: 18 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Centre Hospitalier Universitaire de Nice	•Other	Study Start: December 1, 2020 Primary Completion: December 1, 2022 Study Completion: December 1, 2023 First Posted: November 1, 2019 Results First Posted: No Results Posted Last Update Posted: October 19, 2020	•Nice Hospital, Nice, France
10	NCT04200755	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma Study Documents:	Title Acronym: DupiMorph Other Ids: •Uni-Koeln-3815 •2019-002036-90	Recruiting	•Localized Scleroderma	•Drug: Dupilumab 300Mg Solution for Injection •Other: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •LoSCAT target lesion •mLoSSI all lesions •LoSDI all lesions •Number of lesions •DLQI •RNAseq •RT-qPCR •Adverse events (AEs) •Physical examination •Body weight •and 10 more	Enrollment: 45 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of Cologne	•Other	Study Start: May 19, 2020 Primary Completion: May 2022 Study Completion: May 2022 First Posted: December 16, 2019 Results First Posted: No Results Posted Last Update Posted: July 20, 2020	•Uniklinik Köln, Klinik für Dermatologie und Venerologie, Köln, Germany •Helios St. Elisabeth Klinik Oberhausen, Klinik für Dermatologie, Venerologie und Allergologie, Oberhausen, Germany •Universitäts-Hautklinik Tübingen, Tübingen, Germany

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
11	NCT02851875	Duke Scleroderma Clinic Patient Registry Study Documents:	Title Acronym: Other Ids: Pro00067280	Recruiting	•Scleroderma •Systemic Sclerosis	•Other: Registry	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Change in disease activity as measured by Rodnan Skin Score •Change in disease activity as measured by patient reported Scleroderma Health Associated Questionnaire (SHAQ)	Enrollment: 1000 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Duke University	•Other	Study Start: April 2016 Primary Completion: December 2026 Study Completion: December 2026 First Posted: August 2, 2016 Results First Posted: No Results Posted Last Update Posted: September 22, 2020	•Duke University, Durham, North Carolina, United States
12	NCT04567537	Laser Treatment for the Improvement of Scars and Scleroderma Study Documents:	Title Acronym: Other Ids: 2019P002156	Not yet recruiting	•Scars •Scleroderma	•Device: Laser Treatment	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Physician's Global Assessment Scale	Enrollment: 20 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Massachusetts General Hospital	•Other	Study Start: September 2020 Primary Completion: December 2022 Study Completion: December 2023 First Posted: September 28, 2020 Results First Posted: No Results Posted Last Update Posted: September 28, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
13	NCT04588714	Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention Study Documents:	Title Acronym: Other Ids: HUM00186877	Recruiting	•Scleroderma	•Behavioral: Resilience-based, Energy Management to Enhance Wellbeing (RENEW)	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures: •Feasibility as assessed by intervention participant retention •Feasibility as assessed by the participation in intervention related phone calls •Feasibility as assessed by active participant involvement •Feasibility as assessed by the peer mentor health coach time •Feasibility as assessed by the time spent in preparation for intervention phone calls	Enrollment: 25 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of Michigan	•Other	Study Start: October 27, 2020 Primary Completion: October 31, 2022 Study Completion: October 31, 2022 First Posted: October 19, 2020 Results First Posted: No Results Posted Last Update Posted: November 2, 2020	•University of Michigan, Ann Arbor, Michigan, United States
14	NCT04627857	Effect of the Use of Specific Oral Hygiene Devices on Gingival Health Among Patients With Systemic Sclerosis Study Documents:	Title Acronym: ScleroBross Other Ids: 8014	Not yet recruiting	•Scleroderma Systemic	•Device: Manual toothbrush •Device: Manual toothbrush and water flosser (Philips Sonicare AirFloss) •Device: Sonic toothbrush •Device: Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Investigator) •Primary Purpose: Prevention Outcome Measures: Changing of plaque index between baseline, week 2 and week 4	Enrollment: 100 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Strasbourg, France	•Other	Study Start: January 1, 2021 Primary Completion: January 1, 2024 Study Completion: March 1, 2024 First Posted: November 13, 2020 Results First Posted: No Results Posted Last Update Posted: December 2, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
15	NCT03559465	Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis. Study Documents:	Title Acronym: SCLERO-LB Other Ids: •2016_63 •2017-A02720-53	Recruiting	•Scleroderma, Systemic	•Procedure: skin biopsy •Other: Blood punction	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: •Fibroblast transcriptomic : myofibroblast signature •Fibroblast transcriptomic •Difference in collagen infiltration by PicroSirius red staining between the skin biopsies of the two groups •Difference in the inflammatory infiltrate by immunohistological markings between the skin biopsies of the two groups	Enrollment: 71 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Lille	•Other	Study Start: October 29, 2018 Primary Completion: December 2021 Study Completion: December 2021 First Posted: June 18, 2018 Results First Posted: No Results Posted Last Update Posted: September 17, 2020	•Hôpital Claude Huriez, CHU, Lille, France
16	NCT00074568	Scleroderma Registry Study Documents:	Title Acronym: Registry Other Ids: •NIAMS-108 •N01AR002251-000 •NO1-AR-0-2251	Recruiting	•Systemic Sclerosis •Scleroderma		Study Type: Observational Phase: Study Design: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: Establish National registry of Scleroderma as resource for scleroderma scientific community	Enrollment: 5000 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) •The University of Texas Health Science Center, Houston	•NIH •Other	Study Start: September 2000 Primary Completion: January 2022 Study Completion: First Posted: December 17, 2003 Results First Posted: No Results Posted Last Update Posted: September 29, 2020	•University of Texas - Houston Medical School, Houston, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
17	NCT04683029	A Study of Guselkumab in Participants With Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: •CR108936 •CNTO1959SSC200	Not yet recruiting	•Scleroderma, Systemic	•Drug: Guselkumab Dose 1 •Drug: Guselkumab Dose 2 •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Change from Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 •Change From Baseline in mRSS at Week 52 •Percentage of Participants with Worsening of mRSS at Week 24 and Week 52 •Percentage of Participants Achieving a Score of 0.6 in American College of Rheumatology Combined Response Index in diffuse cutaneous systemic sclerosis (dcSSc) (ACR CRISS) at Week 24 and Week 52 •Change from Baseline in Percent (%) Predicted Forced Vital Capacity (FVC) at Week 24 and Week 52 •Change from Baseline in Digital Ulcer Counts at Week 24 and Week 52 in Participants with Digital Ulcers at Baseline •Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) score at Week 24 and Week 52 •Percentage of Participants with Treatment-emergent Adverse Event (TEAE) •Percentage of Participants with Serious Adverse Event (SAE) •Percentage of Participants with Adverse Events of Special Interest (AESI) •Serum Concentration of Guselkumab	Enrollment: 56 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Janssen Pharmaceutical K.K.	•Industry	Study Start: January 29, 2021 Primary Completion: November 22, 2022 Study Completion: November 22, 2022 First Posted: December 24, 2020 Results First Posted: No Results Posted Last Update Posted: January 22, 2021	•Chukyo Hospital, Aichi, Japan •The University of Tokyo Hospital, Tokyo, Japan •Wakayama Medical University Hospital, Wakayama, Japan •University of Fukui Hospital, Yoshida, Japan

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
18	NCT04380831	TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: •20006 •NCI-2020-02744	Recruiting	•Systemic Scleroderma	•Procedure: Allogeneic Hematopoietic Stem Cell Transplantation •Drug: Cyclophosphamide •Radiation: Intensity-Modulated Radiation Therapy •Procedure: Total-Body Irradiation	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Mean lung dose •Mean kidney dose •Dose homogeneity for lungs, kidneys, and total body •Transplant-related mortality	Enrollment: 15 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•City of Hope Medical Center •National Cancer Institute (NCI)	•Other •NIH	Study Start: January 22, 2021 Primary Completion: July 10, 2023 Study Completion: July 10, 2023 First Posted: May 8, 2020 Results First Posted: No Results Posted Last Update Posted: December 17, 2020	•City of Hope Medical Center, Duarte, California, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
19	NCT04265144	Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre Study Documents:	Title Acronym: SCLERESO Other Ids: CHUBX 2019/42	Recruiting	•Scleroderma •Systemic Sclerosis	•Biological: Blood samples •Other: Biopsy •Other: Bronchoalveolar samples	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Change of the main clinical characteristics of scleroderma patients •Proportion of pulmonary arterial hypertension diagnosis in SSc patients •Proportion of interstitial lung disease diagnosis in SSc patients •Proportion of renal crisis diagnosis in SSc patients •Mean of Rodnan score for the evaluation of disease activity for SSc patients, with higher values mean higher disease activity. •Mean of Diffusing capacity (DLCO) for the evaluation of disease activity for SSc patients •Mean of Forced vital capacity (FVC) for the evaluation of disease activity for SSc patients •Proportion of therapeutic strategies set up for SSc patients	Enrollment: 500 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Bordeaux	•Other	Study Start: June 8, 2020 Primary Completion: June 2030 Study Completion: June 2030 First Posted: February 11, 2020 Results First Posted: No Results Posted Last Update Posted: October 28, 2020	•CHU de Bordeaux - service de rhumatologie, Bordeaux, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
20	NCT04356755	Subcutaneous Injections of Autologous ASC to Heal Digital Ulcers in Patients With Scleroderma. Study Documents:	Title Acronym: ADUSE Other Ids: RC31/17/0447	Recruiting	•Systemic Sclerosis	•Procedure: Adipose tissue harvest •Drug: Autologous ASC •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Proportion of refractory active ischemic digital ulcers healed (complete or partial) •Composite endpoint combining healing (complete or partial) without recurrence and without local or general complications •Percentage of participants with Digital Ulcer complete healing •Percentage of participants with Digital Ulcer partial healing •Percentage of participants with wound surface reduction <50% •Percentage of participants with new Digital Ulcer •Percentage of participants with Digital Ulcer complication •Change from Baseline in Pain Scores •Change from Baseline in severity of Raynaud's phenomenon •Change from Baseline in Digital ischaemia •and 7 more	Enrollment: 32 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Toulouse	•Other	Study Start: September 22, 2020 Primary Completion: March 2023 Study Completion: March 2023 First Posted: April 22, 2020 Results First Posted: No Results Posted Last Update Posted: October 27, 2020	•Grenoble Hospital, Grenoble, France •Lille Hopsital, Lille, France •Marseille Hospital, Marseille, France •Montpellier Hospital, Montpellier, France •Nantes Hospital, Nantes, France •Poitiers Hospital, Poitiers, France •CHU de Toulouse - Hôpital PURPAN-TSA, Toulouse, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
21	NCT03816189	Role of Eosinophil in Fibrogenesis of Systemic Sclerosis Study Documents:	Title Acronym: EOFIB-SSC Other Ids: •2017_10 •2017-A02587-46	Recruiting	•Systemic Sclerosis •Systemic Scleroderma	•Diagnostic Test: Blood test •Diagnostic Test: Skin biopsies	Study Type: Observational Phase: Study Design: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: •Comparison of ECP concentrations in supernatants of eosinophils culture •Comparison of median fluorescence intensities of several surface markers on blood eosinophils, or comparison of percentages of positive cells among all eosinophils for a given marker (flow cytometry) •Gene expression profiles will be compared between SSc patients and healthy controls (whole transcriptome assay) •In skin biopsies: density of eosinophils, extracellular ECP and MBP deposits (absent in healthy skin), and density of eotaxin-1-producing cells will be assessed in damaged skin and apparently healthy skin of SSc patients	Enrollment: 60 Age: 18 Years to 66 Years (Adult, Older Adult) Sex: All	•University Hospital, Lille •GlaxoSmithKline	•Other •Industry	Study Start: October 3, 2018 Primary Completion: December 2020 Study Completion: December 2020 First Posted: January 25, 2019 Results First Posted: No Results Posted Last Update Posted: July 12, 2019	•Hôpital Claude Huriez, CHU, Lille, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
22	NCT03610217	Pragmatic Clinical Trials in Scleroderma Study Documents:	Title Acronym: PCTS Other Ids: 111419	Not yet recruiting	•Scleroderma, Systemic •Sclerosis, Systemic	•Other: Interstitial lung disease induction algorithm •Other: Pulmonary arterial hypertension algorithm •Other: Raynaud's phenomenon algorithm •Other: Digital ulcer algorithm •Other: Inflammatory arthritis algorithm •Other: Gastroesophageal reflux algorithm •Other: Bacterial overgrowth algorithm •Other: Constipation algorithm •Other: Skin involvement algorithm •Other: Pain algorithm	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Sequential Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Forced vital capacity % •Bleeding •Raynaud's phenomenon visual analog scale •Time to the healing of a digital ulcer •Time to the development of a new digital ulcer •Disease activity score 28 •GERD-HRQL •Diarrhea visual analog scale •Constipation visual analog scale •Modified Rodnan skin score •Pain visual analog scale	Enrollment: 400 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of West London •University of Western Ontario, Canada	•Other	Study Start: October 2018 Primary Completion: October 2021 Study Completion: October 2021 First Posted: August 1, 2018 Results First Posted: No Results Posted Last Update Posted: August 6, 2018	•Saint Joseph's Health Care London, London, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
23	NCT04630782	Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease Study Documents:	Title Acronym: Pre Med SSc GI Other Ids: PM-SScGI-01	Recruiting	•Systemic Sclerosis •Scleroderma	•Diagnostic Test: PET-MRI scan	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Inflammatory or fibrosis FDG-PET-MRI imaging biomarkers in VEDOSS/ early SSc or late SSc patients not on immunosuppresive treatment •Inflammatory biomarkers on FDG-PET-MRI imaging after 6 months (primary endpoint) and 12 months (secondary endpoint) of Mycophenolate mofetil treatment. •FDG-PET-MRI imaging over one year in patients with VEDOSS/early SSc not on immunosuppresive treatment •Stool biomarkers	Enrollment: 70 Age: 21 Years to 99 Years (Adult, Older Adult) Sex: All	•Singapore General Hospital •National University Hospital, Singapore •Tan Tock Seng Hospital •Changi General Hospital •Sengkang General Hospital •National University, Singapore •Nanyang Technological University •Duke-NUS Graduate Medical School	•Other	Study Start: April 9, 2020 Primary Completion: January 31, 2023 Study Completion: January 31, 2023 First Posted: November 16, 2020 Results First Posted: No Results Posted Last Update Posted: November 24, 2020	•National University Hospital, Singapore, Singapore •Singapore General Hospital, Singapore, Singapore •Tan Tock Seng Hospital, Singapore, Singapore •Changi General Hospital, Singapore, Singapore •Sengkang General Hospital, Singapore, Singapore
24	NCT03508375	Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis Study Documents:	Title Acronym: SCLEROLUNG Other Ids: •2018-03 •2018-A00066-49	Recruiting	•Systemic Scleroderma	•Biological: blood samples	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: fractalkine levels	Enrollment: 75 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Assistance Publique Hopitaux De Marseille	•Other	Study Start: May 15, 2018 Primary Completion: May 2021 Study Completion: November 2021 First Posted: April 25, 2018 Results First Posted: No Results Posted Last Update Posted: June 19, 2019	•Assistance Publique Hopitaux de Marseille, Marseille, BDR, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
25	NCT04532151	Optical Coherence Tomography Imaging in Systemic Sclerosis Study Documents:	Title Acronym: OCTISS Other Ids: 7630	Not yet recruiting	•Systemic Sclerosis •Early Systemic Sclerosis Without Clinical Scleroderma and Onset < 2 Years	•Diagnostic Test: Non-invasive skin imaging assessment	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Diagnostic Outcome Measures: •Optic density of the papillo-reticular dermis on the dorsal surface of a finger •Optic density of the papillo-reticular dermis at the outer and inner side of the forearm •Modified Rodnan skin score (mRSS) •The thickness of the hypodermis, obtained by HD ultrasound. •The thickness of the dermis, obtained by HD ultrasound •The distribution of tension forces exerted within the dermis by fluid silicone molding techniques •The optic density of the papillo-reticular dermis, 300 µm deep, at the outer and inner side of the forearm will be measured in all three patient groups using OCT.	Enrollment: 60 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Strasbourg, France	•Other	Study Start: October 1, 2020 Primary Completion: October 2023 Study Completion: November 2023 First Posted: August 31, 2020 Results First Posted: No Results Posted Last Update Posted: August 31, 2020	•Hôpitaux Universitaires de Strasbourg, Strasbourg, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
26	NCT04610788	Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH Study Documents:	Title Acronym: CALIPSO Other Ids: •NA_00049022 •R01HL114910-06	Recruiting	•Scleroderma •Pulmonary Artery Hypertension		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Right Ventricular Function as assessed by RHC •Change in pulmonary vascular resistance •Change in arterial elastance •Myofilament contractility •Calcium sensitivity •Number of genes expressed •Number of proteins expressed	Enrollment: 100 Age: 18 Years to 100 Years (Adult, Older Adult) Sex: All	•Johns Hopkins University •National Heart, Lung, and Blood Institute (NHLBI)	•Other •NIH	Study Start: April 15, 2019 Primary Completion: December 31, 2023 Study Completion: December 31, 2023 First Posted: November 2, 2020 Results First Posted: No Results Posted Last Update Posted: November 2, 2020	•Johns Hopkins, Baltimore, Maryland, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
27	NCT02371005	Oral Manifestations of Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: 6026	Recruiting	•Scleroderma, Systemic	•Radiation: Cone Beam Computed Tomography (CBCT)	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: •Measurement of the periodontal ligament space width at mid-root level on Cone Beam Computed Tomography (CBCT) axial views •Radiographic analysis of oro-facial manifestations associated with systemic sclerosis using high-resolution volumetric Cone Beam Computed Tomography (CBCT) exploration	Enrollment: 90 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Strasbourg, France	•Other	Study Start: June 2015 Primary Completion: June 2021 Study Completion: June 2021 First Posted: February 25, 2015 Results First Posted: No Results Posted Last Update Posted: August 25, 2020	•Service de parodontologie, Strasbourg, France
28	NCT04401943	Online Fatigue Intervention Program for People With Scleroderma Study Documents:	Title Acronym: FAME-ISS Other Ids: 19-083	Recruiting	•Systemic Sclerosis	•Other: online fatigue intervention	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Change from baseline Modified Fatigue Impact Scale at 6 weeks •Change from baseline Multidimensional Assessment of Fatigue at 6 weeks	Enrollment: 12 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of New Mexico •University of California, San Diego	•Other	Study Start: May 13, 2020 Primary Completion: April 2021 Study Completion: April 2021 First Posted: May 26, 2020 Results First Posted: No Results Posted Last Update Posted: May 26, 2020	•University of New Mexico, Albuquerque, New Mexico, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
29	NCT03740724	A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) Study Documents:	Title Acronym: Other Ids: FI-SC-001	Recruiting	•Morphea •Scleroderma, Localized •Scleroderma	•Genetic: FCX-013 •Drug: veledimex	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Evaluate the safety of FCX-013 plus veledimex •Evaluate the antifibrotic effects of FCX-013 plus veledimex	Enrollment: 10 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Castle Creek Biosciences, LLC.	•Industry	Study Start: December 18, 2019 Primary Completion: March 2022 Study Completion: January 2036 First Posted: November 14, 2018 Results First Posted: No Results Posted Last Update Posted: January 28, 2021	•Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States
30	NCT03558854	Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients Study Documents:	Title Acronym: Other Ids: 0246/2018	Recruiting	•Systemic Sclerosis	•Drug: Acetylsalicylic acid •Drug: Placebo oral capsule	Study Type: Interventional Phase: Phase 4 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Serum level of thromboxane B2 •Serum level of platelet-derived, endothelial-derived and monocyte-derived microparticles •Serum level of von Willebrand factor •Serum level of endothelin-1 •Digital blood flow	Enrollment: 70 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Federal University of São Paulo	•Other	Study Start: August 28, 2018 Primary Completion: February 2020 Study Completion: May 2020 First Posted: June 15, 2018 Results First Posted: No Results Posted Last Update Posted: November 5, 2019	•Systemic Sclerosis Outpatient Clinic, Hospital São Paulo, São Paulo, SP, Brazil

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
31	NCT04206644	Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages Study Documents:	Title Acronym: SCLERO JAK Other Ids: 35RC19_30043_SC JAK	Not yet recruiting	•Systemic Sclerosis	•Other: biological analysis	Study Type: Observational Phase: Study Design: •Observational Model: Other •Time Perspective: Cross-Sectional Outcome Measures: Concentration of CCL18 in the condition media of MDM from SSc patients	Enrollment: 150 Age: 18 Years to 18 Years (Adult) Sex: All	•Rennes University Hospital	•Other	Study Start: January 6, 2020 Primary Completion: January 6, 2022 Study Completion: February 6, 2026 First Posted: December 20, 2019 Results First Posted: No Results Posted Last Update Posted: December 20, 2019	•Rennes University Hospital, Rennes, France
32	NCT03271333	Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma. Study Documents:	Title Acronym: SCLERO-PID Other Ids: •2015_49 •2016-A00722-49	Recruiting	•Systemic Sclerosis	•Other: lung function tests	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: composite criteria: forced vital capacity and CO diffusing capacity	Enrollment: 70 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•University Hospital, Lille	•Other	Study Start: April 10, 2018 Primary Completion: April 2023 Study Completion: April 2023 First Posted: September 5, 2017 Results First Posted: No Results Posted Last Update Posted: August 27, 2020	•Hôpital Claude Huriez, CHU, Lille, France •AH-HP, Hôpital Saint Antoine, Paris 12, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
33	NCT04137224	Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) Study Documents:	Title Acronym: Other Ids: •IgPro20_2001 •2018-003149-41	Recruiting	•Diffuse Cutaneous Systemic Sclerosis	•Biological: IgPro20 •Biological: IgPro10	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of subjects with adverse events (AEs) for IgPro20 •Percentage of subjects with AEs for IgPro20 •Number and percentage of subjects with treatment emergent adverse events (TEAEs) for IgPro20 •Number and percentage of subjects with seriouis adverse events (SAEs) for IgPro20 •Number and percentage of subjects with adverse events of special interest (AESIs) for IgPro20 •Number of patients with AEs categorized as infusion site reactions (ISRs) for IgPro20 •Percentage of patients with AEs categorized as ISRs for IgPro20 •Rate of ISRs per subject for IgPro20 •Rate of ISRs per infusion for IgPro20 •Onset of ISRs for IgPro20 •and 15 more	Enrollment: 26 Age: 18 Years and older (Adult, Older Adult) Sex: All	•CSL Behring	•Industry	Study Start: September 19, 2019 Primary Completion: August 2021 Study Completion: August 2021 First Posted: October 23, 2019 Results First Posted: No Results Posted Last Update Posted: January 13, 2021	•Royal Adelaide Hospital, Adelaide, South Australia, Australia •St Vincent's Hospital, Melbourne, Victoria, Australia •Hôpital Cochin, Paris, France •Charité Universitätsmedizin Berlin, Berlin, Germany •Uniklinik Köln, innere Medizin, Köln, Germany •Krankenhaus St. Josef, Wuppertal, Germany •University of L'Aquila, L'Aquila, AQ, Italy •Università Politecnica delle Marche, Ancona, Italy •ASST Spedali Civili di Brescia, Brescia, Italy •AOU Careggi, Rheumatology Unit, Firenze, Italy •and 5 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
34	NCT03844061	Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis Study Documents: •Study Protocol and Statistical Analysis Plan •Informed Consent Form	Title Acronym: Other Ids: 2018-2011	Recruiting	•Systemic Sclerosis	•Drug: Belimumab •Drug: Rituximab •Other: Placebo Subcutaneous Injection •Other: Placebo Infusion •Drug: MMF	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Primary Efficacy Outcome: Change in the ACR CRISS at 12 months •Primary Safety Outcome: The proportion of participants who experience at least one Grade 3 or higher adverse event at or before 12 months •Proportion of patients who experience at least one grade 2 or higher adverse event •Number Infectious Adverse Events Across all Participants •Number Adverse Infusion Reactions Across all Participants •Number Injection Site Reactions Across all Participants •Number Adverse Events Across all Participants •Change in the CRISS at 6 months •Change in the MRSS at 6 and 12 months •Change in FVC and DLCO •and 10 more	Enrollment: 30 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	•Hospital for Special Surgery, New York •GlaxoSmithKline	•Other •Industry	Study Start: July 29, 2019 Primary Completion: February 28, 2022 Study Completion: February 28, 2022 First Posted: February 18, 2019 Results First Posted: No Results Posted Last Update Posted: September 17, 2020	•Hospital for Special Surgery, New York, New York, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
35	NCT04212247	Trial on Outpatients With Systemic Sclerosis Treated With Well-Being Therapy or With a Control Therapy Study Documents:	Title Acronym: Other Ids: WBT in SSc	Recruiting	•Systemic Sclerosis	•Behavioral: Well-Being Therapy •Behavioral: Control condition	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Participant) •Primary Purpose: Treatment Outcome Measures: •Disability due to systemic sclerosis •Psychiatric status •Psychosomatic status •Well-being •Psychological well-being •Euthymia •Suffering •Psychological distress •Pain in the body •Mental pain •Psychiatric symptoms •Harmony	Enrollment: 60 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•University of Florence	•Other	Study Start: June 1, 2020 Primary Completion: October 31, 2022 Study Completion: October 31, 2022 First Posted: December 26, 2019 Results First Posted: No Results Posted Last Update Posted: November 5, 2020	•Rheumtoi Unit, Academic Hospital Careggi, Florence, Italy •Fiammetta Cosci, Florence, Italy

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
36	NCT04484948	Utility of Breath-holding Test in Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: H-2006-054-1131	Recruiting	•Systemic Sclerosis	•Other: scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Correlation of breath-holding test with Borg Dyspnea Index •Correlation of breath-holding time with 6 minute walk test (6MWT) distance •Correlation of breath-holding time with oxygen saturation during 6MWT •Correlation of breath-holding time with pulmonary function indices •Correlation of breath-holding time with data on the echocardiography •Correlation of breath-holding time with scleroderma health assessment questionnaire (SHAQ)	Enrollment: 70 Age: 19 Years and older (Adult, Older Adult) Sex: All	•Seoul National University Hospital	•Other	Study Start: August 12, 2020 Primary Completion: June 30, 2022 Study Completion: June 30, 2022 First Posted: July 24, 2020 Results First Posted: No Results Posted Last Update Posted: December 11, 2020	•Seoul National University Hospital, Seoul, Korea, Republic of

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
37	NCT03198689	Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: BV201708	Recruiting	•Diffuse Cutaneous Systemic Sclerosis	•Drug: Brentuximab Vedotin	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Change in skin thickness measured by modified Rodnan Skin Score (mRSS) •Change in mRSS •CRISS score >20% •Change in FVC, % •Change in DLCO, % •Change in physician-assessed disease activity, severity and damage on VASs ranked from 0 to 10 •Change in patient global assessment of health status (VAS 0 to 10) •Change in Health Transition score •Change in SHAQ	Enrollment: 10 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Lawson Health Research Institute •Seagen Inc.	•Other •Industry	Study Start: May 7, 2019 Primary Completion: March 1, 2021 Study Completion: July 1, 2021 First Posted: June 26, 2017 Results First Posted: No Results Posted Last Update Posted: May 24, 2019	•Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
38	NCT04273386	Mouth Handicap in Systemic Sclerosis Questionnaire (MHISS) in Turkish Study Documents:	Title Acronym: Other Ids: ISTANBULC1	Recruiting	•Scleroderma •Systemic Sclerosis •Mouth Diseases	•Other: Evaluation	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Mouth Handicap in Systemic Sclerosis Questionnaire (MHISS) •Scleroderma Health Assessment Questionnaire (SHAQ) •Oral Health Impact Profile (OHIP-14) •Eating Assessment Tool (EAT-10)	Enrollment: 60 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•Istanbul University •Istanbul University-Cerrahpasa	•Other	Study Start: December 2, 2019 Primary Completion: December 2, 2020 Study Completion: February 20, 2021 First Posted: February 18, 2020 Results First Posted: No Results Posted Last Update Posted: September 25, 2020	•Istanbul University-Cerrahpasa, ##stanbul, Turkey
39	NCT04246528	SPIN Self-Management Full-Scale Trial (SPIN-SELF) Study Documents:	Title Acronym: SPIN-SELF Other Ids: 2020-2053	Not yet recruiting	•Scleroderma •Systemic Sclerosis	•Behavioral: SPIN-SELF Program	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures: •Self-Efficacy for Managing Chronic Disease (SEMCD) Scale •Patient Reported Outcomes Measurement Information System (PROMIS-29) profile version 2.0	Enrollment: 440 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Lady Davis Institute	•Other	Study Start: February 15, 2021 Primary Completion: July 31, 2021 Study Completion: April 30, 2023 First Posted: January 29, 2020 Results First Posted: No Results Posted Last Update Posted: January 27, 2021	•Jewish General Hospital, Montréal, Quebec, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
40	NCT04244916	MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis Study Documents:	Title Acronym: SCLERAMAC Other Ids: APHP190933	Recruiting	•Systemic Sclerosis	•Biological: AUC of MPA measure	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Skin efficacy •Pulmonary efficacy.1 •Pulmonary efficacy.2	Enrollment: 50 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Assistance Publique - Hôpitaux de Paris	•Other	Study Start: May 25, 2020 Primary Completion: May 1, 2023 Study Completion: September 1, 2023 First Posted: January 28, 2020 Results First Posted: No Results Posted Last Update Posted: July 7, 2020	•Cochin hospital, AP-HP, Paris, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
41	NCT03708718	Prednisolone in Early Diffuse Systemic Sclerosis Study Documents:	Title Acronym: PRedSS Other Ids: 119220	Recruiting	•Systemic Sclerosis	•Drug: Prednisolone 5 mg •Drug: Placebo oral capsule; From August 2020 'no additional treatment'	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures: •Health Assessment Questionnaire Disability Index (HAQ-DI) •modified Rodnan Skin Score (mRSS) •Quality of life and functional ability - Assessed by Questionnaire •Pain and disability - Assessed by Questionnaire •Functional ability - Assessed by Questionnaire •Pain associated with itch - Assessed by Questionnaire •Hand function - Assessed by Questionnaire •Fatigue - Assessed by Questionnaire •Anxiety and depression - Assessed by questionnaire •Health related quality of life - Assessed by Questionnaire •and 3 more	Enrollment: 72 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Prof. Ariane herrick •Versus Arthritis •University of Manchester	•Other	Study Start: December 21, 2017 Primary Completion: June 2021 Study Completion: September 2021 First Posted: October 17, 2018 Results First Posted: No Results Posted Last Update Posted: November 6, 2020	•Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, Aberdeenshire, United Kingdom •Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom •Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom •Glasgow Royal Infirmary -, Glasgow, Lanarkshire, United Kingdom •Aintree University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom •Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom •Royal National Hospital For Rheumatic Diseases - Royal United Hospitals Bath NHS Foundation Trust, Bath, Somerset, United Kingdom •Royal Hallamshire Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom •Freeman Hospital - The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom •The Dudley Group NHS Foundation Trust, Dudley, West Midlands, United Kingdom •and 4 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
42	NCT03222492	Brentuximab Vedotin for Systemic Sclerosis Study Documents:	Title Acronym: BRAVOS Other Ids: •DAIT ITN075AI •ITN075AI •NIAID CRMS ID#: 38418	Recruiting	•Diffuse Cutaneous Systemic Sclerosis •Scleroderma •dcSSc	•Biological: Brentuximab Vedotin •Biological: Placebo	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Sequential Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures: •Proportion of participants who experience at least one Grade 3 or higher adverse event •Proportion of participants who experience at least one Grade 2 or higher adverse event •Proportion of participants with Grade 2 or higher peripheral neuropathy •Proportion of participants with Grade 3 or higher neutropenia •Proportion of participants with any of the following Grade 3 or higher adverse events by week 48: peripheral neuropathy, neutropenia, infectious, infusion reactions and/ or progressive multifocal leukoencephalopathy •Proportion of participants with infectious adverse events Grade 3 or higher	Enrollment: 24 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•National Institute of Allergy and Infectious Diseases (NIAID) •Immune Tolerance Network (ITN) •Seagen Inc.	•NIH •Other •Industry	Study Start: September 20, 2017 Primary Completion: January 2023 Study Completion: January 2023 First Posted: July 19, 2017 Results First Posted: No Results Posted Last Update Posted: January 19, 2021	•UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States •Georgetown University Medical Center: Division of Rheumatology, Washington, District of Columbia, United States •Boston University School of Medicine: Rheumatology Section, Scleroderma Clinical Centers, Boston, Massachusetts, United States •University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States •Hospital for Special Surgery, New York: Division of Rheumatology, New York, New York, United States •Duke University Medical Center: Division of Rheumatology and Immunology, Durham, North Carolina, United States •University of Pittsburgh Medical Center: Division of Rheumatology and Clinical, Pittsburgh, Pennsylvania, United States •Medical University of South Carolina: Division of Rheumatology & Immunology, Charleston, South Carolina, United States •University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States •Toronto Mount Sinai Hospital, Toronto, Ontario, Canada

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
43	NCT04301596	Assessment of Nutritional Status in Systemic Sclerosis Study Documents:	Title Acronym: NUTRISCLER Other Ids: •RECHMPL19_0409 •UF7840	Recruiting	•Systemic Sclerosis	•Other: Collection of data	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Incidence of malnutrition •Idetification of risk factors associated with malnutrition •Success of the nutritional intervention	Enrollment: 150 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Montpellier	•Other	Study Start: June 12, 2020 Primary Completion: June 12, 2023 Study Completion: October 12, 2023 First Posted: March 10, 2020 Results First Posted: No Results Posted Last Update Posted: June 24, 2020	•Montpellier University Hospital, Montpellier, France
44	NCT04303208	Plasmacytoid Dendritic Cells and Toll Like Receptor 8 in Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: Pdcs and TLR8 in Ssc	Not yet recruiting	•Systemic Sclerosis	•Procedure: 2 ml of whole blood sample will be collected on EDTA tube	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •the difference between the amount of plasmacytoid dendritic cells in both groups •detection of toll like receptor 8 in systemic sclerosis patients	Enrollment: 80 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Assiut University	•Other	Study Start: December 2020 Primary Completion: September 2022 Study Completion: December 2022 First Posted: March 11, 2020 Results First Posted: No Results Posted Last Update Posted: March 11, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
45	NCT04515706	Iguratimod in Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: IGU	Not yet recruiting	•Systemic Sclerosis, Diffuse	•Drug: Iguratimod •Drug: Placebo	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 •Number of Grade 3 (Severe) or Higher Adverse Events That Occur Throughout the Study •Number of Grade 2 (Moderate) or Higher Adverse Events That Occur Throughout the Study •Provisional American College of Rheumatology Combined Response Index (CRISS) Systemic Sclerosis •Scleroderma Clinical Trials Consortium Damage Index •Change in Modified Rodnan Skin Score (mRSS) •Change in Skin Thickness	Enrollment: 20 Age: 19 Years to 74 Years (Adult, Older Adult) Sex: All	•RenJi Hospital	•Other	Study Start: January 1, 2021 Primary Completion: January 31, 2023 Study Completion: January 31, 2024 First Posted: August 17, 2020 Results First Posted: No Results Posted Last Update Posted: August 17, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
46	NCT04132206	Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients Study Documents:	Title Acronym: ScleroBiotique Other Ids: 18-30 MEDIBIOTE 2	Recruiting	•Systemic Sclerosis	•Other: stool sampling	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Differences on gut microbiota composition (bacterial populations) of ScS overtime, at different taxonomic levels (from phyla to species if technique allows) versus healthy controls.	Enrollment: 60 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hôpital Européen Marseille	•Other	Study Start: October 8, 2019 Primary Completion: October 8, 2022 Study Completion: April 8, 2023 First Posted: October 18, 2019 Results First Posted: No Results Posted Last Update Posted: October 18, 2019	•Hôpital Euroépen Marseille, Marseille, Paca, France •Hôpital Européen Marseille, Marseille, France
47	NCT04001556	RElevance of UltraSonography for Assessing Salivary Gland Involvement in Systemic Sclerosis (SSc) Study Documents:	Title Acronym: REUSSI-SSc Other Ids: 35RC18_9905	Not yet recruiting	•Systemic Sclerosis	•Diagnostic Test: Minor Salivary gland Biopsy •Diagnostic Test: ARFI •Diagnostic Test: MSG US	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Diagnostic Outcome Measures: •Ultrasonography characteristics of major salivary glands •Variants of the Salaffi score •Biopsy of the minor salivary glands •Evaluation of the presence or absence of objective criteria of Sjogren •Clinical evaluation of systemic scleroderma lesions	Enrollment: 75 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Rennes University Hospital	•Other	Study Start: June 30, 2019 Primary Completion: July 20, 2019 Study Completion: June 30, 2022 First Posted: June 28, 2019 Results First Posted: No Results Posted Last Update Posted: July 5, 2019	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
48	NCT04680975	Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Study Documents:	Title Acronym: dcSSC Other Ids: KD025-215	Recruiting	•Diffuse Cutaneous Systemic Sclerosis	•Drug: Belumosudil	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Efficacy: CRISS at Week 24 •Efficacy: CRISS at Weeks 8, 16, 36, and 52 •Efficacy: mRSS at Week 24 •Efficacy: Forced Vital Capacity (FVC) at Week 24 •Efficacy: Physician Global Assessment at Week 24 •Efficacy: Patient Global Assessment at Week 24 •Efficacy: Change in FVC at Weeks 8, 16, 36, and 52 from Baseline •Efficacy: Change in mRSS at Weeks 8, 16, 36, and 52 from Baseline •Efficacy: Change in Physician Global Assessment at Weeks 8, 16, 36, and 52 from Baseline •Efficacy: Change in Patient Global Assessment at Weeks 8, 16, 36, and 52 from Baseline •and 3 more	Enrollment: 15 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Kadmon Corporation, LLC	•Industry	Study Start: December 24, 2020 Primary Completion: October 1, 2022 Study Completion: October 1, 2022 First Posted: December 23, 2020 Results First Posted: No Results Posted Last Update Posted: January 28, 2021	•University of California, Los Angeles Medical Center, Los Angeles, California, United States •Yale University School of Medicine, New Haven, Connecticut, United States •Northwestern University, Chicago, Illinois, United States •Columbia University Medical Center, New York, New York, United States •University of Utah, Salt Lake City, Utah, United States •Virginia Mason Medical Center, Seattle, Washington, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
49	NCT03459716	Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension Study Documents:	Title Acronym: BOSS-PH Other Ids: IRB 10033SM	Recruiting	•Scleroderma •Pulmonary Hypertension	•Other: No intervention	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Composite pulmonary hypertension detection score	Enrollment: 56 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Louisiana State University Health Sciences Center in New Orleans •Scleroderma Foundation •Tulane University Health Sciences Center •University Medical Center-New Orleans	•Other	Study Start: June 1, 2018 Primary Completion: April 1, 2021 Study Completion: April 1, 2021 First Posted: March 9, 2018 Results First Posted: No Results Posted Last Update Posted: June 27, 2018	•University Medical Center-New Orleans, New Orleans, Louisiana, United States
50	NCT01895244	Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis Study Documents:	Title Acronym: AST-MOMA Other Ids: AST MOMA	Recruiting	•Scleroderma •Cardiac Involvement •Autologous Stem Cell Transplantation	•Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Efficay - Overall survival •Safety - Treatment related mortality •Time to engraftment •Progression free survival •Efficacy - Lung function test and Skin	Enrollment: 44 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•University Hospital Tuebingen	•Other	Study Start: September 2012 Primary Completion: September 2021 Study Completion: September 2024 First Posted: July 10, 2013 Results First Posted: No Results Posted Last Update Posted: November 19, 2020	•University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology, Tuebingen, Germany

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
51	NCT04300426	Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) Study Documents:	Title Acronym: ReSScue Other Ids: 2019-004400-35	Recruiting	•Systemic Sclerosis	•Drug: "ACHIM" as solute (10^9 intestinal microbes/ml)	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •• Change from baseline to week 12 in UCLA GIT score item diarrhea or bloating, depending which was the worst symptom at baseline evaluated separately for each patient •• Safety and tolerability assessed by adverse event (AE) monitoring, physical examination and clinical laboratory testing from baseline to the end of the study period •• Change from baseline to week 12 in total UCLA GIT score •• Change from baseline to week 12 in UCLA GIT score item diarrhea •• Change from baseline to week 12 in UCLA GIT score item bloating	Enrollment: 70 Age: 18 Years to 85 Years (Adult, Older Adult) Sex: All	•Oslo University Hospital •South-Eastern Norway Regional Health Authority •Haukeland University Hospital •St. Olavs Hospital •University Hospital of North Norway	•Other	Study Start: September 24, 2020 Primary Completion: June 30, 2022 Study Completion: June 30, 2022 First Posted: March 9, 2020 Results First Posted: No Results Posted Last Update Posted: October 9, 2020	•Haukeland University Hospital, Bergen, Norway •Oslo University Hospital, Oslo, Norway •University hospital of North Norway, Tromsø, Norway •St. Olavs hospital, Trondheim university hospital, Trondheim, Norway

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
52	NCT04166552	Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: EHP-101-SS01	Recruiting	•Diffuse Cutaneous Systemic Sclerosis	•Drug: Patients will be randomized to receive EHP-101 or Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Incidence and severity of Treatment Emergent Adverse Events •Treatment effect of EHP-101 compared to placebo as measured by the American College of Rheumatology composite response index in diffuse cutaneous Systemic Sclerosis •Treatment effect of EHP-101 compared to placebo in modified Rodnan skin score •Treatment effect of EHP-101 compared to placebo in forced vital capacity percent predicted •Treatment effect of EHP-101 compared to placebo in physician global assessment score •Treatment effect of EHP-101 compared to placebo in patient global assessments score •Treatment effect of EHP-101 compared to placebo in Scleroderma Health Assessment Questionnaire - Disability Index	Enrollment: 36 Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	•Emerald Health Pharmaceuticals Inc. •Iqvia Pty Ltd	•Industry	Study Start: June 11, 2020 Primary Completion: March 2021 Study Completion: July 2021 First Posted: November 18, 2019 Results First Posted: No Results Posted Last Update Posted: January 12, 2021	•Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona, United States •Pacific Arthritis Care Center, Los Angeles, California, United States •Inland Rheumatology Clinical Trials, Upland, California, United States •Central Florida Pulmonary Group, Altamonte Springs, Florida, United States •Life Clinical Trials, Margate, Florida, United States •Novel Clinical Research Center, Miami, Florida, United States •Clinical Research of West Florida, Tampa, Florida, United States •Northwestern University, Evanston, Illinois, United States •Cleveland Clinic, Cleveland, Ohio, United States •Royal Adelaide Hospital, Adelaide, Australia •and 4 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
53	NCT04725786	Clinical Relevance of Thoracic Echography for the Early Diagnosis of Interstitial Lung Disease in Systemic Scleroderma - Pilot Study Study Documents:	Title Acronym: PRECOSS Other Ids: •DR20098 •2020-A03249-30	Not yet recruiting	•Systemic Sclerosis	•Other: thoracic echography	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: •Presence of interstitial syndrome on echography •Ventilatory mechanics •Pulmonary gas exchange •Exercise capacity •Circulatory response •Dyspnoea •Assessment of Quality of life •Cough	Enrollment: 30 Age: 18 Years to 100 Years (Adult, Older Adult) Sex: All	•University Hospital, Tours	•Other	Study Start: March 15, 2021 Primary Completion: September 15, 2022 Study Completion: September 15, 2022 First Posted: January 27, 2021 Results First Posted: No Results Posted Last Update Posted: January 27, 2021	
54	NCT04478994	A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) Study Documents:	Title Acronym: Other Ids: HZNP-TEP-001	Recruiting	•Diffuse Cutaneous Systemic Sclerosis	•Biological: TEPEZZA •Other: Placebo	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Proportion of participants who experience a treatment emergent adverse event (TEAE) through Week 24 in subjects with dcSSc.	Enrollment: 25 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	•Horizon Therapeutics USA, Inc. •Horizon Pharma USA, Inc.	•Industry	Study Start: November 2020 Primary Completion: April 2022 Study Completion: September 2022 First Posted: July 21, 2020 Results First Posted: No Results Posted Last Update Posted: November 3, 2020	•Pacific Arthritis Care Center, Los Angeles, California, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
55	NCT04563481	Effectiveness of Telerehabilitation on Scleroderma Study Documents:	Title Acronym: Other Ids: ISTANBULC	Not yet recruiting	•Scleroderma •Scleroderma, Systemic •Scleroderma Associated Digital Ulcer •Hand Rheumatism •Physiotherapy •Rehabilitation	•Other: Hand Therapy via Telerehabilitation •Other: Hand Therapy by Physiotherapist	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Hand Mobility in Scleroderma (HAMIS) •9-Hole Peg Test •Scleroderma Health Assessment Questionnaire (SHAQ) •Semmes Weinstein Monofilaman Test •Pittsburgh Sleep Quality Index (PSQI)	Enrollment: 32 Age: 18 Years to 55 Years (Adult) Sex: All	•Istanbul University	•Other	Study Start: February 1, 2021 Primary Completion: November 1, 2021 Study Completion: December 30, 2021 First Posted: September 24, 2020 Results First Posted: No Results Posted Last Update Posted: December 22, 2020	•Tugba Civi Karaaslan, Istanbul, Buyukcekmece, Turkey

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
56	NCT04647890	Effects of FT011 in Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: CER-FT011-SSc01	Not yet recruiting	•Scleroderma, Systemic •Scleroderma, Diffuse •Sclerosis, Systemic	•Drug: FT011 •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •FT011 levels in plasma •Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study •mRSS change from Baseline •%FVC change from Baseline •Physician Global Assessment change from Baseline •Patient Global Assessment change from Baseline •Scleroderma HAQ-DI change from Baseline •Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) at Week 12 •Scleroderma Clinical Trial Consortium Damage Index (SCTC-DI) change from Baseline •5-D Itch Scale change from Baseline	Enrollment: 30 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Certa Therapeutics	•Industry	Study Start: February 2021 Primary Completion: March 2022 Study Completion: April 2022 First Posted: December 1, 2020 Results First Posted: No Results Posted Last Update Posted: December 1, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
57	NCT04440592	Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: MT-7117-G02	Recruiting	•Diffuse Cutaneous Systemic Sclerosis	•Drug: MT-7117 •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •The ACR CRISS composite score (0-1) at Week 52 •Change in Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline up to week 52 •Change in percent predicted forced vital capacity (%pFVC) from baseline up to week 52 •Change in Patient Global Assessment from baseline up to week 52 •Change in Physician Global Assessment from baseline up to week 52 •Change in modified Rodnan Skin Score (mRSS) from baseline from baseline up to week 52 •ACR CRISS Score up to Week 39 •ACR CRISS score responder (CRISS>=0.6) from baseline up to week 52	Enrollment: 72 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Mitsubishi Tanabe Pharma Development America, Inc.	•Industry	Study Start: December 31, 2020 Primary Completion: January 2023 Study Completion: February 2023 First Posted: June 19, 2020 Results First Posted: No Results Posted Last Update Posted: December 14, 2020	•Arizona Arthritis, Glendale, Arizona, United States •University of Arizona Arthritis Center, Tucson, Arizona, United States •UCSD School of Medicine, La Jolla, California, United States •Pacific Arthritis Care Center, Los Angeles, California, United States •UCLA Medical Center, Los Angeles, California, United States •The Board of Trustees of the Leland Stanford Junior University, Redwood City, California, United States •Yale School of Medicine - The Anlyan Center (TAC) for Medical Research & Education, New Haven, Connecticut, United States •GNP Research, Hollywood, Florida, United States •University of Miami Miller School of Medicine, Miami, Florida, United States •Millennium Research, Ormond Beach, Florida, United States •and 10 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
58	NCT04684225	Telerehabilitation Approach on Individuals With Hand-Affected Scleroderma Study Documents:	Title Acronym: Other Ids: ISTANBULC2	Not yet recruiting	•Scleroderma •Scleroderma, Systemic •Scleroderma Associated Digital Ulcer •Hand Rheumatism •Physiotherapy •Rehabilitation	•Other: Hand Therapy via Telerehabilitation •Other: Hand Therapy via home-exercises	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Hand Mobility in Scleroderma (HAMIS) •9-Hole Peg Test •Scleroderma Health Assessment Questionnaire (SHAQ) •Semmes Weinstein Monofilaman Test	Enrollment: 42 Age: 18 Years to 55 Years (Adult) Sex: All	•Istanbul University	•Other	Study Start: December 30, 2020 Primary Completion: December 30, 2021 Study Completion: April 30, 2022 First Posted: December 24, 2020 Results First Posted: No Results Posted Last Update Posted: December 24, 2020	
59	NCT01959815	Novel Screening Strategies for Scleroderma PAH Study Documents:	Title Acronym: Other Ids: HUM00074818	Recruiting	•Pulmonary Arterial Hypertension •Scleroderma		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Development of pulmonary arterial hypertension	Enrollment: 200 Age: 30 Years and older (Adult, Older Adult) Sex: All	•University of Michigan	•Other	Study Start: October 2013 Primary Completion: October 2021 Study Completion: October 2021 First Posted: October 10, 2013 Results First Posted: No Results Posted Last Update Posted: September 30, 2020	•University of Michigan, Ann Arbor, Michigan, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
60	NCT04040322	Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) Study Documents:	Title Acronym: Other Ids: ES-301	Recruiting	•Raynaud's Phenomenon Secondary to Systemic Sclerosis	•Drug: Placebo IV infusion •Drug: Iloprost Injection, for intravenous use	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Frequency of symptomatic RP attacks	Enrollment: 180 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Eicos Sciences, Inc.	•Industry	Study Start: October 14, 2019 Primary Completion: June 30, 2021 Study Completion: June 30, 2021 First Posted: July 31, 2019 Results First Posted: No Results Posted Last Update Posted: December 8, 2020	•Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States •Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States •University of Arizona - Arthritis Research Center, Tucson, Arizona, United States •Cedars-Sinai Medical Center, Los Angeles, California, United States •University of California, Los Angeles Medical Center, Los Angeles, California, United States •Stanford University Medical Center, Palo Alto, California, United States •University of California San Francisco, San Francisco, California, United States •Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States •Northwestern Medical Faculty Foundation, Chicago, Illinois, United States •University Medical Center New Orleans, New Orleans, Louisiana, United States •and 20 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
61	NCT03726398	CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Study Documents:	Title Acronym: CRUSADE Other Ids: IIS-02801	Recruiting	•Interstitial Lung Disease •Scleroderma •Pulmonary Hypertension	•Drug: Opsumit 10 Mg Tablet	Study Type: Interventional Phase: •Phase 2 •Phase 3 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Prevention Outcome Measures: •Change in exercise pulmonary vascular resistance (PVR) •Change in right ventricular pulmonary vascular hemodynamic coupling (RVPA). •Change in maximal oxygen consumption (V02 max). •Change in pulmonary impedance.	Enrollment: 26 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Franz Rischard, DO •National Jewish Health •University of Pittsburgh •University of Arizona	•Other	Study Start: September 1, 2018 Primary Completion: January 31, 2020 Study Completion: December 1, 2020 First Posted: October 31, 2018 Results First Posted: No Results Posted Last Update Posted: April 2, 2019	•University of Arizona, Tucson, Arizona, United States
62	NCT03438032	Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD Study Documents:	Title Acronym: Other Ids: SP0044402	Recruiting	•Fibrosis Lung •Systemic Sclerosis	•Diagnostic Test: Bronchoscopy with lavage	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Cross-Sectional Outcome Measures: Single-cell RNA-seq analysis	Enrollment: 20 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Northwestern University	•Other	Study Start: June 28, 2018 Primary Completion: June 30, 2021 Study Completion: June 30, 2021 First Posted: February 19, 2018 Results First Posted: No Results Posted Last Update Posted: September 10, 2020	•Northwestern University, Chicago, Illinois, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
63	NCT03919799	KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: KD025-209	Recruiting	•System; Sclerosis •Diffuse Cutaneous Systemic Sclerosis	•Drug: Belumosudil (KD025) •Drug: Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Efficacy: CRISS Response of Belumosudil vs. Placebo at Week 24 •Efficacy: CRISS Response of Belumosudil vs. Placebo at Week 52 •Efficacy: mRSS of Belumosudil vs. Placebo at Week 24 •Efficacy: FVC of Belumosudil vs. Placebo at Week 24 •Efficacy: Physician Global Assessment of Belumosudil vs. Placebo at Week 24 •Efficacy: Patient Global Assessment of Belumosudil vs. Placebo at Week 24 •Efficacy: SHAQ-DI of Belumosudil vs. Placebo at Week 24 •Efficacy: mRSS of Belumosudil at Week 52 Compared to Baseline •Efficacy: FVC of Belumosudil at Week 52 Compared to Baseline •Efficacy: Physician Global Assessment of Belumosudil Compared to Baseline •and 8 more	Enrollment: 60 Age: 18 Years to 100 Years (Adult, Older Adult) Sex: All	•Kadmon Corporation, LLC	•Industry	Study Start: July 9, 2019 Primary Completion: December 2021 Study Completion: May 2022 First Posted: April 18, 2019 Results First Posted: No Results Posted Last Update Posted: January 28, 2021	•Viable Research Management/ Titan Clinical Solutions, Phoenix, Arizona, United States •Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States •University of California - San Diego, La Jolla, California, United States •Pacific Arthrirtis Care Center, Los Angeles, California, United States •University of California - Los Angeles, Los Angeles, California, United States •Stanford University Medical Center, Palo Alto, California, United States •University of Connecticut, Farmington, Connecticut, United States •Yale University School of Medicine, New Haven, Connecticut, United States •Georgetown University, Washington, District of Columbia, United States •St. Francis Medical Institute, Clearwater, Florida, United States •and 18 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
64	NCT03374618	Neutrophil Extracellular Traps in Systemic Sclerosis Study Documents:	Title Acronym: NET-SSC Other Ids: PO17014	Recruiting	•Systemic Lupus Erythematosus •Systemic Sclerosis	•Other: Blood sample	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: •Quantification of neutrophil extracellular traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls. •Analysis of the composition of neutrophil extracellular traps •Analysis of the cytokines influencing NETs production in vitro	Enrollment: 120 Age: 18 Years and older (Adult, Older Adult) Sex: All	•CHU de Reims	•Other	Study Start: October 6, 2017 Primary Completion: October 6, 2021 Study Completion: October 7, 2021 First Posted: December 15, 2017 Results First Posted: No Results Posted Last Update Posted: February 5, 2020	•Damien JOLLY, Reims, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
65	NCT04650659	Functional Exercise Tests in Patients With Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: •SSc6MWT2020 •1-16-02-270-20	Not yet recruiting	•Scleroderma, Systemic •Lung Diseases, Interstitial •Pulmonary Arterial Hypertension	•Diagnostic Test: 6-minute walk test part one •Diagnostic Test: 6-minute walk test part two •Diagnostic Test: 1-minute sit-to-stand test •Diagnostic Test: 4-meters gait speed test	Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Cross-Sectional Outcome Measures: •Examine the validity of peripheral oxygen saturation measurement during 6-minute walk test in patients with Systemic Sclerosis. •Examine the correlation between the 6-minute walk test, the 1-minute sit-to-stand test, and the 4-meter gait speed test in patients with Systemic Sclerosis. •Investigate the correlation between functional exercise tests and the severity of pulmonary involvement in patients with Systemic Sclerosis.	Enrollment: 83 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of Aarhus •The Danish Rheumatism Association	•Other	Study Start: January 4, 2021 Primary Completion: August 31, 2021 Study Completion: August 31, 2021 First Posted: December 3, 2020 Results First Posted: No Results Posted Last Update Posted: December 3, 2020	•The Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
66	NCT03856853	Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease Study Documents:	Title Acronym: Other Ids: GNI-F647-1701	Recruiting	•Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)	•Drug: Pirfenidone •Other: placebo	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: Relative change from baseline (%) of FVC%	Enrollment: 144 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•Beijing Continent Pharmaceutical Co, Ltd. •Shanghai Genomics, Inc. •GNI-EPS Pharmaceuticals, Inc. (GNI Group)	•Industry	Study Start: June 15, 2018 Primary Completion: February 10, 2021 Study Completion: May 10, 2021 First Posted: February 27, 2019 Results First Posted: No Results Posted Last Update Posted: February 27, 2019	•Zhang, Ling, Beijing, Beijing, China

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
67	NCT04675502	Effects of a Supervised Exercise Program and a Home Exercise Program in Patients With Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: 3701-GOA	Recruiting	•Systemic Sclerosis •Home Exercise •Aerobic Exercise	•Other: supervised Exercise training •Other: home exercise trainig	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Change in Forced Vital Capacity •Change in Forced Expiratory Volume in One Second •Change in Forced expiratory volume in one second / Forced vital capacity •Change in diffusion capacity •Change in Maximal Expiratory Pressure •Change in Maximal Inspiratory Pressure •Change in functional capacity •Change in peripheral muscle strength •Change in severity of dyspnoea •Change in fatigue •and 3 more	Enrollment: 40 Age: 35 Years to 65 Years (Adult, Older Adult) Sex: All	•Dokuz Eylul University	•Other	Study Start: June 10, 2018 Primary Completion: January 20, 2021 Study Completion: February 15, 2021 First Posted: December 19, 2020 Results First Posted: No Results Posted Last Update Posted: December 19, 2020	•Dokuz Eylül Üniversitesi School of Physical Therapy and Rehabilitation, #zmir, #zmir, Turkey, Turkey

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
68	NCT04363021	Is a History of Pre-eclampsia a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis? Study Documents:	Title Acronym: PREVASCLERO Other Ids: PREVASCLERO (29BRC20.0080)	Recruiting	•Systemic Sclerosis •Preeclampsia •Vascular Complications		Study Type: Observational Phase: Study Design: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: •History of pre-eclampsia before systemic sclerosis diagnosis •Risk factors for vascular phenotype in sclerodermic women with a previous pregnancy longer than 6 months	Enrollment: 378 Age: 18 Years to 90 Years (Adult, Older Adult) Sex: Female	•University Hospital, Brest	•Other	Study Start: July 6, 2020 Primary Completion: July 6, 2022 Study Completion: October 2022 First Posted: April 27, 2020 Results First Posted: No Results Posted Last Update Posted: December 3, 2020	•CHU de Clermont-Ferrand, Clermont-Ferrand, France •CHU de Dijon, Dijon, France •CHU de Lille, Lille, France •CHU de Limoges, Limoges, France •CHU de Nantes, Nantes, France •CHU de Nice, Nice, France •CHU de Rennes, Rennes, France •CHU de Strasbourg, Strasbourg, France •CHU de Toulouse, Toulouse, France •CHU de Tours, Tours, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
69	NCT04223817	7.0 Tesla Resonance Magnetic Imaging of the Hand in Systemic Sclerosis Study Documents:	Title Acronym: PREM'S Other Ids: 2019-A02760-57	Not yet recruiting	•Systemic Sclerosis •7.0 Tesla Magnetic Resonance Imaging •Hand Vascular Involvement •Hand Osteoarticular Involvement	•Device: 7.0 T RMI	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Screening Outcome Measures: •Frequency of hand osteoarticular involvement in SSc and control subjects in 7.0 T RMI •Arterial pattern in the hand of SSc patients and control subjects in 7.0 T RMI •Correlation between hand osteoarticular involvement in 7.0 T RMI and general and SSc-related factors, including hand vascular involvement, in SSc patients •Correlation between hand arterial involvement in 7.0 T RMI and general and SSc-related factors, including hand osteoarticular involvement, in SSc patients •Sodium articular concentration in the hand in 7.0 T RMI in SSc patients and control subjects	Enrollment: 50 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Poitiers University Hospital	•Other	Study Start: December 1, 2020 Primary Completion: December 1, 2022 Study Completion: December 1, 2022 First Posted: January 10, 2020 Results First Posted: No Results Posted Last Update Posted: September 23, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
70	NCT01729611	Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension Study Documents:	Title Acronym: Other Ids: Tonella1	Recruiting	•Pulmonary Hypertension		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Base Line	Enrollment: 140 Age: 17 Years to 90 Years (Child, Adult, Older Adult) Sex: All	•The Cleveland Clinic	•Other	Study Start: December 2013 Primary Completion: March 2021 Study Completion: July 2021 First Posted: November 20, 2012 Results First Posted: No Results Posted Last Update Posted: March 31, 2020	•Cleveland Clinic, Cleveland, Ohio, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
71	NCT03630211	Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis Study Documents:	Title Acronym: SSc Other Ids: PRO18050360	Recruiting	•Systemic Sclerosis •Diffuse Sclerosis Systemic •Interstitial Lung Disease •Pulmonary Hypertension	•Drug: Cyclophosphamide •Drug: Mesna •Drug: Rituximab •Drug: Alemtuzumab •Drug: Thiotepa •Drug: GM-CSF •Drug: Intravenous immunoglobulin •Radiation: Total Body Irradiation	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •High Dose Immunoablative therapy-Safety •Death •Respiratory Failure •Renal Failure •The occurrence of cardiomyopathy •Treatment-related mortality (TRM) •High Dose Immunoablative therapy-Treatment Effect •An increase of mRSS (modified Rodnan skin score) by #5 points for skin score •Increase by #25% if the baseline mRSS > 20. •Worsening of > 10% of FVC (pulmonary function testing) •and 3 more	Enrollment: 8 Age: 16 Years to 70 Years (Child, Adult, Older Adult) Sex: All	•Paul Szabolcs •University of Pittsburgh	•Other	Study Start: July 31, 2018 Primary Completion: August 1, 2023 Study Completion: August 1, 2025 First Posted: August 14, 2018 Results First Posted: No Results Posted Last Update Posted: November 27, 2020	•Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States •University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States •University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
72	NCT04464434	Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Study Documents:	Title Acronym: UPSIDE Other Ids: NL72607.041.20	Recruiting	•Systemic Sclerosis •Systemic Scleroses, Diffuse •Scleroderma •Scleroderma, Diffuse •Autologous Stem Cell Transplantation •Cyclophosphamide •Mycophenolate Mofetil •Treatment Strategy	•Procedure: Upfront autologous HSCT	Study Type: Interventional Phase: Phase 3 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Number of patients who survive without major events (event free survival) •Number of patients who survive without disease progression (Progression-free survival) •Number of patients who die due to complications related to the treatment (Treatment related mortality) •Number of patient alive after 24 months (Overall mortality) •Number of CTCAE toxicity advserse events •The area under the curve (AUC) of the CRISS over time •Changes in skin involvement (modified Rodnan Skin Score) •Changes in cardiac function(Left Ventricular Ejection Fraction) •Changes in pulmonary function •Changes in health related quality of life EQ-5D-5L index •and 11 more	Enrollment: 120 Age: 18 Years to 65 Years (Adult, Older Adult) Sex: All	•UMC Utrecht •ZonMw: The Netherlands Organisation for Health Research and Development •Boehringer Ingelheim •Miltenyi Biotec, Inc.	•Other •Industry	Study Start: September 17, 2020 Primary Completion: September 17, 2025 Study Completion: February 1, 2026 First Posted: July 9, 2020 Results First Posted: No Results Posted Last Update Posted: January 28, 2021	•University Hospital Ghent, Ghent, Belgium •University Hospital Leuven, Leuven, Belgium •University Hospital Zagreb, Zagreb, Croatia •Ruhr University Bochum, Bochum, Germany •University Hospital Freiburg, Freiburg, Germany •Universitats Klinikum Tuebingen, Tuebingen, Germany •Universitats Klinikum Wurzburg, Würzburg, Germany •ASST Pini-CTO, Milan, Italy •Amsterdam Rheumatology Centre, Amsterdam, Netherlands •University Medical Centre Leiden, Leiden, Netherlands •and 4 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
73	NCT02682511	Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Study Documents:	Title Acronym: Other Ids: CPI-IFE-004	Recruiting	•Scleroderma, Diffuse •Scleroderma, Systemic •Scleroderma, Limited •Sclerosis, Progressive Systemic •Skin Diseases •Connective Tissue Diseases •Pathologic Processes •Autoimmune Diseases	•Drug: Oral Ifetroban •Drug: Oral Placebo	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Incidence of adverse events (AEs) and Serious AEs (SAEs) •Change from baseline in forced vital capacity (FVC) •Change from baseline in diffusion capacity for carbon monoxide (DLCO) •Change from baseline in the modified Rodnan skin score (mRSS)	Enrollment: 34 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	•Cumberland Pharmaceuticals	•Industry	Study Start: January 2017 Primary Completion: December 2022 Study Completion: December 2022 First Posted: February 15, 2016 Results First Posted: No Results Posted Last Update Posted: August 31, 2020	•UCLA, Los Angeles, California, United States •New Life Medical Research Center, Inc., Hialeah, Florida, United States •Cleveland Clinic - Florida, Weston, Florida, United States •Johns Hopkins University, Baltimore, Maryland, United States •Massachusetts General Hospital, Boston, Massachusetts, United States •Boston University School of Medicine, Boston, Massachusetts, United States •Hospital for Special Surgery, New York, New York, United States •Thomas Jefferson University, Philadelphia, Pennsylvania, United States •Medical University of South Carolina, Charleston, South Carolina, United States •Vanderbilt University Medical Center, Nashville, Tennessee, United States •and 4 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
74	NCT04356287	Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis Study Documents:	Title Acronym: CARE-SSc Other Ids: MP-05-2020-2251	Not yet recruiting	•Sclerosis, Systemic •Mesenchymal Stem Cells	•Biological: UCMSC •Other: Placebo	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Measure of safety one month after first infusion (adverse events) •Measure of safety one month after second infusion (adverse events) •Change in modified Rodnan skin score (mRss) between Month 0 and Month 12	Enrollment: 18 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Marie Hudson, MD •Assistance Publique - Hôpitaux de Paris •University Paris 7 - Denis Diderot •Université de Montréal •Medical University of South Carolina •Centre hospitalier de l'Université de Montréal (CHUM) •McGill University Health Centre/ Research Institute of the McGill University Health Centre •Sir Mortimer B. Davis - Jewish General Hospital	•Other	Study Start: October 2020 Primary Completion: September 2022 Study Completion: December 2022 First Posted: April 22, 2020 Results First Posted: No Results Posted Last Update Posted: April 27, 2020	
75	NCT04325217	Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan Study Documents:	Title Acronym: Other Ids: 1199-0387	Recruiting	•Lung Diseases, Interstitial	•Drug: Nintedanib	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Incidence of adverse drug reactions (ADRs)	Enrollment: 600 Age: Child, Adult, Older Adult Sex: All	•Boehringer Ingelheim	•Industry	Study Start: April 15, 2020 Primary Completion: March 31, 2024 Study Completion: June 30, 2024 First Posted: March 27, 2020 Results First Posted: No Results Posted Last Update Posted: January 12, 2021	•Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
76	NCT03059979	The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis (SSc) Study Documents:	Title Acronym: Other Ids: HHaE	Recruiting	•Systemic Sclerosis •Raynaud Phenomena	•Drug: Methylprednisolone •Other: sodium chloride	Study Type: Interventional Phase: Early Phase 1 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures: •the change in capillary density from baseline •change in selected biomarkers: the interferon signature in peripheral blood from baseline •change in nail fold capillary changes other than capillary density and giant capillaries from baseline •change in modified Rodnan skin score (mRSS) from baseline •presence of puffy fingers from baseline •presence of synovitis from baseline •presence of tendon friction rubs from baseline •fulfilling EULAR/ACR (American College of Rheumatology)classificatior from baseline criteria for SSc from baseline •pulmonary function tests from baseline •presence of interstitial lung disease from baseline •and 7 more	Enrollment: 30 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Radboud University	•Other	Study Start: January 2017 Primary Completion: July 1, 2021 Study Completion: July 1, 2021 First Posted: February 23, 2017 Results First Posted: No Results Posted Last Update Posted: November 29, 2019	•Radboudumc, Rheumatology department, Nijmegen, Gelderland, Netherlands

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
77	NCT02298777	Metabolomic Analysis of Systemic Sclerosis Study Documents:	Title Acronym: SCLEROMICS Other Ids: 5723	Recruiting	•Scleroderma (Limited and Diffuse) •Undifferentiated Connective Tissue Disease •Raynaud Disease •Vascular Disease •Healthy Control Subjects	•Procedure: - Skin biopsy - Urine sample - Blood sample	Study Type: Observational Phase: Study Design: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: •change of metabolomics profiles between SSc beginners (<3 years) and SSc established forms (> 3 years) at baseline inclusion. •Study and comparison of discriminating metabolomics profiles for prognosis, diagnosis and exploration of SSc.	Enrollment: 140 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Strasbourg, France	•Other	Study Start: December 2014 Primary Completion: June 2023 Study Completion: July 2023 First Posted: November 24, 2014 Results First Posted: No Results Posted Last Update Posted: July 27, 2020	•CHU, Dijon, France •Hôpitaux privés de Metz, Metz, France •CHU, Nancy, France •CHU, Reims, France
78	NCT03588845	The Small Intestine Bacterial Overgrowth Study Pilot Study Documents: •Study Protocol	Title Acronym: SIBO Other Ids: CODIM-MBM-16-282	Recruiting	•Systemic Sclerosis •Small Intestinal Bacterial Overgrowth	•Other: Treatment Protocol •Other: Standard of Care	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Investigator) •Primary Purpose: Diagnostic Outcome Measures: Determine if protocol treatment is effective	Enrollment: 500 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Canadian Scleroderma Research Group •Canadian Institutes of Health Research (CIHR)	•Other	Study Start: February 15, 2019 Primary Completion: April 1, 2021 Study Completion: September 1, 2021 First Posted: July 17, 2018 Results First Posted: No Results Posted Last Update Posted: October 17, 2019	•John's Hopkins, Baltimore, Maryland, United States •Saint Vincent's, Melbourne, Australia

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
79	NCT03268330	Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: ROMMIFISS	Recruiting	•System; Sclerosis		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Correlation between Migration Inhibitory Factor and some of the clinical manifestations of Systemic Sclerosis.	Enrollment: 40 Age: 17 Years to 70 Years (Child, Adult, Older Adult) Sex: All	•Assiut University	•Other	Study Start: September 2021 Primary Completion: October 2021 Study Completion: November 2021 First Posted: August 31, 2017 Results First Posted: No Results Posted Last Update Posted: January 12, 2021	•Assiut University Hospital, Assiut, Egypt •Assuit University hospital, Assuit, Egypt

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
80	NCT04118725	Muscular Respiratory Involvement and Systemic Sclerosis Study Documents:	Title Acronym: SIROCO Other Ids: 2019-A01047-50	Recruiting	•Systemic Sclerosis •Diaphragm Defect •Respiratory Insufficiency •Pulmonary Function Test •Diaphragmatic Electromyography •Muscular Weakness	•Diagnostic Test: Pulmonary function test	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Screening Outcome Measures: •Frequency of diaphragmatic involvement among ScS patients with dyspnea and/or with suspected respiratory muscular involvement on pulmonary function tests (PFT) •Sensitivity, specificity, positive and negative predictive value of pulmonary function tests compared to diaphragmatic involvement confirmed by EMG and Pdi among ScS patients with suspected pulmonary muscular involvement on PFT •Sensitivity, specificity, positive and negative predictive value of dyspnea compared to diaphragmatic involvement confirmed by EMG and Pdi •Correlation between diaphragmatic involvement confirmed by EMG and and/or Pdi and dyspnea •Correlation between diaphragmatic involvement confirmed by EMG and and/or Pdi and general and ScS-related factors •Correlation between diaphragmatic involvement confirmed by EMG and and/or Pdi and suspected muscular respiratory on pulmonary function test •Correlation between diaphragmatic involvement confirmed by EMG and and/or Pdi and quality of life and functional disability	Enrollment: 110 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Poitiers University Hospital	•Other	Study Start: October 21, 2019 Primary Completion: August 31, 2021 Study Completion: August 31, 2021 First Posted: October 8, 2019 Results First Posted: No Results Posted Last Update Posted: December 23, 2019	•Chu de Poitiers, Poitiers, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
81	NCT04095351	Connective Tissue Diseases and Lung Manifestations Study Documents:	Title Acronym: Colipris Other Ids: 20190506-2003	Recruiting	•Connective Tissue Diseases •Interstitial Lung Disease •Systemic Sclerosis	•Diagnostic Test: Pulmonary function test •Diagnostic Test: Imaging •Biological: Blood sampling	Study Type: Observational Phase: Study Design: •Observational Model: Other •Time Perspective: Prospective Outcome Measures: •Decline in forced vital capacity •Increase in the modified Rodnan Skin Score •Decline in Diffusion capacity for carbon monoxide	Enrollment: 120 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	•Medical University Innsbruck •Boehringer Ingelheim	•Other •Industry	Study Start: December 9, 2019 Primary Completion: March 1, 2021 Study Completion: October 1, 2034 First Posted: September 19, 2019 Results First Posted: No Results Posted Last Update Posted: May 27, 2020	•Medical University Innsbruck, Department of Internal Medicine II, Innsbruck, Austria
82	NCT03858842	Non-interventional Study Describing Epidemiology, Prognosis and Patient Healthcare Costs in France, 2010-2017 Study Documents:	Title Acronym: PROGRESS Other Ids: 69HCL19_0027	Not yet recruiting	•Lung Diseases, Interstitial •Lung Disease With Systemic Sclerosis	•Other: epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Retrospective Outcome Measures: •Incidence of PF-ILD and SSc-ILD patients •Prevalence of PF-ILD and SSc-ILD patients •characteristics of PF-ILD and SSc-ILD patients •healthcare resource use of PF-ILD and SSc-ILD patients •associated costs of PF-ILD and SSc-ILD patients •mortality for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) in France. •Forced Vital Capacity for the non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung (PF-ILD) in France.	Enrollment: 100 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Hospices Civils de Lyon	•Other	Study Start: March 2019 Primary Completion: December 2019 Study Completion: December 2019 First Posted: March 1, 2019 Results First Posted: No Results Posted Last Update Posted: March 8, 2019	•Hôpital Cardiologique Louis Pradel, Bron, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
83	NCT02789670	Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Study Documents:	Title Acronym: B-MS Other Ids: •2013_35 •2014-A00248-39	Recruiting	•Multiple Sclerosis •Systemic Sclerosis	•Other: Blood sample collection	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Comparison of the production of IL-10 and IL-6 by B cells in MS patients and the control group at inclusion time point •Comparison of the production of IL-10 and IL-6 by B cells in MS patients and the control group at the different time points of the study •Comparison of the production of IL-10 and IL-6 by B cells in the MS patient subgroups at the inclusion time point •Comparison of the production of IL-10 and IL-6 by B cells in the MS patient subgroups at the different time points of the study •Comparison B cell subset distribution in MS patients and the control group •Comparison B cell subset distribution •Comparison B cell subset distribution in MS patients versus the control group at the different time points of the study	Enrollment: 160 Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	•University Hospital, Lille	•Other	Study Start: July 2014 Primary Completion: December 2020 Study Completion: December 2020 First Posted: June 3, 2016 Results First Posted: No Results Posted Last Update Posted: September 11, 2020	•CHRU de Lille, Lille, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
84	NCT01808937	Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository Study Documents:	Title Acronym: MAC Other Ids: 032007021	Recruiting	•Scleroderma, Localized •Morphea •Frontal Linear Scleroderma en Coup de Sabre •Scleroderma, Circumscribed •Scleroderma, Linear	•Other: Morphea	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Activity/damage measurement in morphea as scored on the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) •Quality of life scores measured by the Dermatology Life Quality Index (DLQI)	Enrollment: 500 Age: up to 90 Years (Child, Adult, Older Adult) Sex: All	•University of Texas Southwestern Medical Center	•Other	Study Start: May 2007 Primary Completion: January 2022 Study Completion: January 2023 First Posted: March 11, 2013 Results First Posted: No Results Posted Last Update Posted: April 10, 2020	•UT Southwestern Medical Center - Department of Dermatology, Dallas, Texas, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
85	NCT02370693	Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Study Documents:	Title Acronym: Other Ids: •R34 •1R34HL122558-01	Recruiting	•Interstitial Lung Disease •ILD •Systemic Sclerosis •Scleroderma	•Drug: Bortezomib •Drug: Placebo •Drug: Mycophenolate mofetil	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures: •Safety and Tolerability of bortezomib with mycophenolate mofetil assessed by the incidence of serious adverse events •Effect of bortezomib with mycophenolate mofetil on quality of life measured by Promis-29 SF-36, and St. George Respiratory Dyspnea Score questionnaires •Effect of bortezomib with mycophenolate mofetil on skin fibrosis measured by the Modified Rodnan Skin Score •Effect of bortezomib with mycophenolate mofetil on lung function measured by change in Forced Vital Capacity during pulmonary function tests	Enrollment: 30 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Northwestern University •National Heart, Lung, and Blood Institute (NHLBI)	•Other •NIH	Study Start: March 2016 Primary Completion: June 2020 Study Completion: June 2020 First Posted: February 25, 2015 Results First Posted: No Results Posted Last Update Posted: September 4, 2019	•Northwestern University, Chicago, Illinois, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
86	NCT03819777	Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) Study Documents:	Title Acronym: VOC-PAH Other Ids: NL57351.068.17	Recruiting	• Pulmonary Arterial Hypertension • Systemic Sclerosis • Systemic Lupus		Study Type: Observational Phase: Study Design: • Observational Model: Other • Time Perspective: Prospective Outcome Measures: • Determining unique inflammatory VOC profiles in exhaled air in three groups of patients: IPAH, PAH-CTD and CTD without PAH. • Correlation between unique inflammatory VOCs to well-established biomarkers of immune activation and inflammation in PAH-CTD and idiopathic PAH. • Change (#, delta) from baseline in selective inflammatory VOC profiles after 3, 6 and 12 months in all patients treated with PAH and/ or immunsuppressive medication.	Enrollment: 150 Age: 18 Years and older (Adult, Older Adult) Sex: All	• Maastricht University Medical Center	• Other	Study Start: March 1, 2018 Primary Completion: October 31, 2021 Study Completion: January 31, 2022 First Posted: January 29, 2019 Results First Posted: No Results Posted Last Update Posted: March 3, 2020	• Maastricht University Medical Center, Maastricht, Netherlands

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
87	NCT04335396	Screening Patients With Diabetes Mellitus for the Presence of Skin Disorder of Scleredema Study Documents:	Title Acronym: Other Ids: 22400-5/2018 EÜIG	Recruiting	•Diabetes Mellitus •Diabetes Complications •Scleroderma-Like Changes •Scleredema Adultorum		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •presence of atherogen dyslipidemia •presence of incresed non-HDL cholesterol level of the sera •Hepatic steatosis index •Number of vascular complications in patients' medical histories, earlier, than our investigation time •Prevalence of polyneuropathy	Enrollment: 150 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University of Pecs	•Other	Study Start: May 28, 2018 Primary Completion: May 30, 2020 Study Completion: May 28, 2023 First Posted: April 6, 2020 Results First Posted: No Results Posted Last Update Posted: April 8, 2020	•Dept. Rheumatology and Immunology, University of Pécs, Pécs, Baranya, Hungary
88	NCT04264728	Adult-onset Generalized Morphea Study Documents:	Title Acronym: MORPHEA Other Ids: 7551	Recruiting	•Generalized Morphea		Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Retrospective Outcome Measures: Retrospective study of generalized morphea in adult patients consulted in dermatology departments	Enrollment: 100 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Strasbourg, France	•Other	Study Start: December 1, 2019 Primary Completion: April 2020 Study Completion: April 2020 First Posted: February 11, 2020 Results First Posted: No Results Posted Last Update Posted: February 13, 2020	•Service de dermatologie - Hôpital Civil de Strasbourg, Strasbourg, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
89	NCT03582800	Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Study Documents:	Title Acronym: ITS-PILOT Other Ids: I17004 (ITS-PILOT)	Recruiting	•Systemic Sclerosis •Dermatomyositis •iPPSD2	•Drug: STS	Study Type: Interventional Phase: Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Change of the percentage of volume of the treated calcifications / ossifications •Change of the volume of the treated calcifications / ossifications •Adverse events •Change of the Hounsfield density of the treated ectopic calcifications/ ossifications •Change of the percentage of patient with a clinically pertinent variation in pain •Change of the percentage of patients with a clinically pertinent variation in quality of life	Enrollment: 40 Age: 6 Months and older (Child, Adult, Older Adult) Sex: All	•University Hospital, Limoges	•Other	Study Start: January 6, 2020 Primary Completion: March 2023 Study Completion: March 2023 First Posted: July 11, 2018 Results First Posted: No Results Posted Last Update Posted: September 29, 2020	•CHU de BORDEAUX, Bordeaux, France •ApHp - Hôpital Bicêtre, Le Kremlin-Bicêtre, France •CHU de Limoges, Limoges, France •CHU de MONTPELLIER, Montpellier, France •ApHp - hôpital Lariboisière, Paris, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
90	NCT03446339	Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE) Study Documents:	Title Acronym: PAH Other Ids: PH_Screening_1.4.2 ver.1	Recruiting	•Connective Tissue Diseases •Systemic Sclerosis •Systemic Lupus Erythematosus		Study Type: Observational Phase: Study Design: •Observational Model: Case-Only •Time Perspective: Prospective Outcome Measures: •Prevalence of asymptomatic pulmonary hypertension in Chinese patients with connective tissue diseases •Clinical predictor of Echocardiography for pulmonary hypertension in Chinese patients with connective tissue diseases •Clinical predictor of BNP assay for pulmonary hypertension in Chinese patients with connective tissue diseases	Enrollment: 1800 Age: 18 Years and older (Adult, Older Adult) Sex: All	•The University of Hong Kong	•Other	Study Start: August 3, 2017 Primary Completion: December 2020 Study Completion: December 2020 First Posted: February 26, 2018 Results First Posted: No Results Posted Last Update Posted: November 25, 2020	•The University of Hong Kong, Hong Kong, China
91	NCT03679845	Study to Assess Sarilumab in Halting Progression of Morphea Study Documents:	Title Acronym: Other Ids: 2018P002128	Recruiting	•Morphea, Plaque Form	•Drug: Sarilumab	Study Type: Interventional Phase: •Phase 1 •Phase 2 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •efficacy of sarilumab in plaque type morphea •Physician Global Assessment of Activity (PGA-A)	Enrollment: 20 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Massachusetts General Hospital •Regeneron Pharmaceuticals	•Other •Industry	Study Start: September 1, 2019 Primary Completion: November 5, 2020 Study Completion: November 5, 2020 First Posted: September 20, 2018 Results First Posted: No Results Posted Last Update Posted: September 9, 2020	•CURTIS (Massachusetts General Hospital), Boston, Massachusetts, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
92	NCT03473912	Meir Medical Center Rheumatologic Biobank Study Documents:	Title Acronym: Other Ids: MMC17-0116CTIL	Recruiting	•Rheumatoid Arthritis •Lupus Erythematosus, Systemic •Systemic Sclerosis •IgG4-related Disease •Sjogren's Syndrome		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: collecting samples	Enrollment: 500 Age: 18 Years to 120 Years (Adult, Older Adult) Sex: All	•Meir Medical Center	•Other	Study Start: April 16, 2018 Primary Completion: November 2037 Study Completion: November 2037 First Posted: March 22, 2018 Results First Posted: No Results Posted Last Update Posted: March 11, 2019	•Meir Medical Center, Kfar Saba, Israel
93	NCT03444805	EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2) Study Documents:	Title Acronym: NISSC-2 Other Ids: ADWP 8410025	Recruiting	•Autoimmune Diseases	•Procedure: Autologous HSCT	Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Progression free survival (PFS), •Treatment related toxicity •100 days Treatment Related Mortality (100d TRM) •Overall Survival (OS) •Use of prednisone equivalent •Use of immunosuppressive drugs •Use of post-transplant biotherapies •Response to treatment •Infectious complications, CMV / EBV reactivation •Secondary autoimmune diseases and secondary malignancy •Immune reconstitution	Enrollment: 60 Age: 18 Years and older (Adult, Older Adult) Sex: All	•European Group for Blood and Marrow Transplantation	•Other	Study Start: July 1, 2019 Primary Completion: December 31, 2021 Study Completion: March 30, 2023 First Posted: February 23, 2018 Results First Posted: No Results Posted Last Update Posted: September 3, 2019	•Badoglio Manuela- EBMT Paris Office, Paris, France

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
94	NCT01884051	Hormonal, Metabolic, and Signaling Interactions in PAH Study Documents:	Title Acronym: Other Ids: P01HL108800	Recruiting	•Idiopathic Pulmonary Arterial Hypertension •Heritable Pulmonary Arterial Hypertension •Scleroderma Associated Pulmonary Arterial Hypertension •Appetite Suppressant Associate PAH		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Ratio of sex hormone metabolites •Evaluation of insulin resistance in pulmonary arterial hypertension patients/Clinical trial of Metformin in Pulmonary Arterial Hypertension •Mechanism, safety, and efficacy of ACE-2 (Angiotensin Converting Enzyme 2) in the treatment of PAH. •Clinical Trial of Metformin in Pulmonary Arterial Hypertension •Mechanism, safety, and efficacy of ACE-2 in the treatment of PAH.	Enrollment: 1899 Age: up to 90 Years (Child, Adult, Older Adult) Sex: All	•Vanderbilt University Medical Center	•Other	Study Start: September 2012 Primary Completion: July 2022 Study Completion: July 2022 First Posted: June 21, 2013 Results First Posted: No Results Posted Last Update Posted: June 16, 2020	•Vanderbilt University Medical Center, Nashville, Tennessee, United States
95	NCT03269630	New Orleans Pulmonary Hypertension Biobank Study Documents:	Title Acronym: NO-PH Biobank Other Ids: LSU	Recruiting	•Pulmonary Hypertension •Systemic Sclerosis •Mixed Connective Tissue Disease •Heart Failure With Normal Ejection Fraction •Healthy	•Other: No intervention. Biospecimen collection only	Study Type: Observational Phase: Study Design: •Observational Model: Other •Time Perspective: Prospective Outcome Measures: Collection of biospecimens	Enrollment: 450 Age: 18 Years and older (Adult, Older Adult) Sex: All	•Louisiana State University Health Sciences Center in New Orleans	•Other	Study Start: December 29, 2017 Primary Completion: October 2027 Study Completion: October 2027 First Posted: September 1, 2017 Results First Posted: No Results Posted Last Update Posted: March 11, 2019	•University Medical Center-New Orleans, New Orleans, Louisiana, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
96	NCT01931644	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions Study Documents:	Title Acronym: Other Ids: SAN-BB-01	Recruiting	•All Diagnosed Health Conditions •ADD/ADHD •Alopecia Areata •Ankylosing Spondylitis •Asthma •Atopic Dermatitis Eczema •Beta Thalassemia •Bipolar Disorder •Breast Cancer •Celiac Disease •and 51 more		Study Type: Observational Phase: Study Design: •Observational Model: Cohort •Time Perspective: Cross-Sectional Outcome Measures: Biospecimen & Clinical Data Collection	Enrollment: 20000 Age: 18 Years to 100 Years (Adult, Older Adult) Sex: All	•Sanguine Biosciences	•Industry	Study Start: July 2013 Primary Completion: August 2025 Study Completion: December 2040 First Posted: August 29, 2013 Results First Posted: No Results Posted Last Update Posted: October 8, 2019	•Sanguine Biosciences, Los Angeles, California, United States
97	NCT04402086	Rheumatology Patient Registry and Biorepository Study Documents:	Title Acronym: Other Ids: 2000026608	Recruiting	•Rheumatic Diseases •Adult Onset Still Disease •Ankylosing Spondylitis •Psoriatic Arthritis •Reactive Arthritis •Antiphospholipid Syndrome •Systemic Lupus Erythematosus •Behcet Disease •Dermatomyositis •Polymyositis •and 10 more		Study Type: Observational Phase: Study Design: •Observational Model: Other •Time Perspective: Prospective Outcome Measures: Correlate outcomes and biomarkers of rheumatic diseases	Enrollment: 5000 Age: 18 Years to 99 Years (Adult, Older Adult) Sex: All	•Yale University	•Other	Study Start: August 4, 2020 Primary Completion: June 1, 2030 Study Completion: June 1, 2040 First Posted: May 26, 2020 Results First Posted: No Results Posted Last Update Posted: August 20, 2020	•Yale New Haven Hospital, New Haven, Connecticut, United States

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
98	NCT03800017	Skeletal Muscle Function in Interstitial Lung Disease Study Documents:	Title Acronym: Other Ids: H18-02059	Not yet recruiting	• Interstitial Lung Disease • Idiopathic Pulmonary Fibrosis • Hypersensitivity Pneumonitis • Scleroderma • Nonspecific Interstitial Pneumonia	• Biological: Hyperoxia	Study Type: Interventional Phase: Not Applicable Study Design: • Allocation: Non-Randomized • Intervention Model: Parallel Assignment • Masking: Single (Participant) • Primary Purpose: Basic Science Outcome Measures: • Change in standardized dyspnea score during the constant load exercise test (visit 3) • Change in standardized dyspnea score during the constant load exercise test (visit 4) • Change in leg muscle strength measured following the constant load exercise test (visit 3) • Change in leg muscle strength measured following the constant load exercise test (visit 4) • Quadriceps muscle oxidative capacity measured using near-infrared spectroscopy • Quadriceps muscle volume measured using magnetic resonance imaging	Enrollment: 40 Age: 40 Years to 80 Years (Adult, Older Adult) Sex: All	• University of British Columbia	• Other	Study Start: September 1, 2021 Primary Completion: August 31, 2022 Study Completion: August 31, 2022 First Posted: January 10, 2019 Results First Posted: No Results Posted Last Update Posted: November 3, 2020	

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
99	NCT03816345	Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Study Documents:	Title Acronym: Other Ids: •NCI-2019-00241 •10204 •UM1CA186688	Recruiting	•Advanced Malignant Neoplasm •Autoimmune Disease •Crohn Disease •Dermatomyositis •Inflammatory Bowel Disease •Metastatic Malignant Neoplasm •Multiple Sclerosis •Rheumatoid Arthritis •Sjogren Syndrome •Systemic Lupus Erythematosus •and 3 more	•Biological: Nivolumab	Study Type: Interventional Phase: Phase 1 Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Incidence of adverse events •Change in disease assessments •Overall response rate •Changes in serum chemokines and circulating immune cells over time •Gene expression in normal tissues •Clinical measures of interest	Enrollment: 264 Age: 18 Years and older (Adult, Older Adult) Sex: All	•National Cancer Institute (NCI)	•NIH	Study Start: April 4, 2019 Primary Completion: August 31, 2022 Study Completion: August 31, 2022 First Posted: January 25, 2019 Results First Posted: No Results Posted Last Update Posted: January 11, 2021	•Stanford Cancer Institute Palo Alto, Palo Alto, California, United States •University of California Davis Comprehensive Cancer Center, Sacramento, California, United States •Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States •Yale University, New Haven, Connecticut, United States •Emory University Hospital/ Winship Cancer Institute, Atlanta, Georgia, United States •Johns Hopkins University/ Sidney Kimmel Cancer Center, Baltimore, Maryland, United States •National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States •National Institutes of Health Clinical Center, Bethesda, Maryland, United States •Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States •Dana-Farber Cancer Institute, Boston, Massachusetts, United States •and 7 more

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funder Type	Dates	Locations
100	NCT04334031	Deployment o the Multidisciplinary Prospective Cohort Imminent Study Documents:	Title Acronym: IMMINeNT Other Ids: •2018_82 •2019-A01309-48	Not yet recruiting	•Chronic Inflammatory Disease •Angioedema •Severe Asthma •Lupus •Atopic Dermatitis •Psoriatic Arthritis •Multiple Sclerosis •Systemic Sclerosis	•Genetic: Biobanking with genetic analysis •Other: SF-12 questionnaire	Study Type: Interventional Phase: Not Applicable Study Design: •Allocation: N/A •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Change of SLEDAI for lupus •Change of Medsger score •Change of EDSS for multiple sclerosis •Change of BASDAI for psoriatic arthristis •Change of Longhurst criteria for hereditary angioedema •Change of number of flares for atopic dermatitis •Change of number of exacerbations for severe asthma •Change of 12-Item Short-Form Health Survey (SF-12) - quality of life scale •number of participant with severe infectious events	Enrollment: 2000 Age: 18 Years and older (Adult, Older Adult) Sex: All	•University Hospital, Lille •FHU IMMINeNT	•Other	Study Start: January 2021 Primary Completion: January 2031 Study Completion: January 2031 First Posted: April 3, 2020 Results First Posted: No Results Posted Last Update Posted: November 25, 2020	

6 additional studies not shown